News & Events

EpiEndo expands operations with new facility in Sweden’s largest life science cluster

EpiEndo expands operations with new facility in Sweden’s largest life science cluster

REYKJAVIK, ICELAND – 21 April 2022 – EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has expanded its operations with a new laboratory facility in Sweden and new staff hired to key positions.

The facility is located in Solna, Sweden, giving EpiEndo a footprint in the expansive Stockholm-Uppsala life science cluster. It is close to the Karolinska Institute and Karolinska University Hospital, which is consistently ranked one of the world’s best medical schools, enabling EpiEndo to take advantage of the intellectual and technical infrastructure and attract key industry talent.

EpiEndo has already recruited an experienced team of chemists who will be working with its unique technology at the fully operational new facility to develop new therapeutic molecules addressing inflammatory disorders. The new team is led by Fredrik Lehmann who has rejoined the EpiEndo leadership team as Head of Research, with responsibility for both Chemistry and Biology research.

EpiEndo’s talented team is located across Europe, including in Denmark, Sweden, Iceland, and the UK. Since the Company’s €20m Series A fundraise in August 2021, this team has grown from 9 permanent employees to 19 - working both virtually and in its facilities in Sweden and Iceland.

In addition to Fredrik Lehmann, key recent hires include the appointment of Stefan Petursson as CFO in April 2022, and the transition of Ginny Norris from consultant to an employed CMO.

EpiEndo’s CEO, Maria Bech, commented: “Opening this new chemistry facility in a key regional life-sciences hub is a significant milestone for us. It is the first time that we have had dedicated resources focused on expanding our pipeline of unique, non-antibiotic, epithelial barrier-enhancing, orally available treatments for inflammatory disorders.

“We’re proud to have attracted a talented team and are confident we have the capabilities in place to maximise the potential of our technology.”


Chemists working in EpiEndo’s facility, high resolution images available on request

About EpiEndo Pharmaceuticals (

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on enhancement of epithelial barrier integrity as a critical pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human lung tissue and other organs such as the gut and skin. Compromised integrity of this barrier is implicated in the progression and non-resolution of several chronic inflammatory diseases.

EpiEndo is developing a proprietary portfolio of non-antibiotic macrolide drugs called Barriolides, with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic diseases of the lung and other organs where there is significant unmet medical need. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD. 

For more information please contact


back to news


Rozi MorrisAssociate Partner

Dr Katie DuffellAccount Manager